SUMMARY
INTRODUCTION
The chemotherapeutic drugs act through cellular kinetics. Since the mitotic capacity of tumor cells is higher than normal cells, these cells are more susceptible to the cytotoxic drugs. However, the effects of chemotherapeutic agents are not specific to cells.
Therefore, normal cells with high mitotic index (e.g. bone marrow and intestinal mucosa) are highly affected by cancer chemotherapy.
The side effects of chemotherapeutic agents may be cumulative and irreversible. This may result in changes in therapeutic doses, cessation of the treatment and even death. Hence, the toxicity does not allow to prolong disease-free survival time and to increase the quality of life of the patient, which are the goals of the treatment. Cumulative toxicity is rare with chemotherapeutic agents used in gynecologic oncology in usual doses and generally it is tolerable.
Paclitaxel is a chemotherapeutic agent that is widely used for gynecologic malignancies and acts through microtubules. It has been entered in gynecologic oncology practice as a consequence of the studies about evolving the treatment of ovarian cancer.
Currently, the combination of taxane (mostly paclitaxel) plus platinum (mostly carboplatin) is the standard treatment modality for the epithelial ovarian cancers and the preferred treatment procedure for advanced stage endometrial cancers.
The most common and major side effects of cytotoxic cancer therapy are bone marrow suppression, gastrointestinal system symptoms and alopecia.
Alopecia becomes noticeable when at least 50% of hair is lost. More than 80% of the patients given antimicrotubule agents (paclitaxel etc.) may develop alopecia during chemotherapy (1) .
In this study, we aimed to determine alopecia caused by the combination of paclitaxel/platinum, which is used often as first-line therapy in gynecologic oncology.
MATERIALS AND METHOD
The toxicity data of 470 patients, who underwent The attention was paid to the patients to have the performance status 2 or below according to the Gynecologic Oncology Group standards prior to the chemoterapy; that is bone marrow, hepatic and renal functions were adequate (leukocyte count ≥3.000/ml; thrombocyte count ≥100.000/ml; hemoglobin level ≥10 mg/dl; total bilirubin, AST and ALT levels below twice the corresponding upper limit of normal; glomerular filtration rate 60 ml/min and over).
Chemotherapy was initiated with paclitaxel in a dose of 175 mg/m 2 . The calculated dose was given by 3-hour infusion in 500 cc of 0.09% NaCl solution. Then, 1-hour infusion of carboplatin calculated by AUC=6 in 1000 cc of 5% dextrose solution or 2-hour infusion of cisplatin in a dose of 75 mg/m 2 in 1000 cc of 0.09% NaCl solution together with 500 cc of 20% mannitol was done. The drugs were given strictly in that order, because there are studies demonstrating that the patients tolerate well in that way (2) . The treatment was given with 21-day intervals.
As premedication, dexamethasone infusion was done, every ten days.
The toxicity was assessed by one researcher (IK) according to the criteria established by the World Health organization (Table I) (3) . The statistical analyses were done using Chi-square test on SPSS (Statistical Package for Social Sciences) ver. 17. software running under Windows XP operating system. The p value <0.05 was set to be significant.
RESULTS
The median age was 55 years (18 to 63) in the group of the patients. Of the patients, 186 patients were given the combination of paclitaxel/cisplatin and 284 patients were administered paclitaxel/carboplatin combination.
The primarily involved organs were ovaries (403 patients), endometrium (38 patients), ovaries and endometrium (13 patients), uterine tubes (seven patients), primary peritoneal serous papillary carcinoma (seven patients) and cervix (two patients). (Table II) . As the sessions progress, alopecia developed more often (Table III) . After the first session, 61 patients (13%) did not have alopecia, while 46 patients (9.8%) developed grade 3 alopecia. Grade 3 alopecia was found in 49.6% of the patients after 2nd session, in 73.4% of the patients after 3rd session, in 85.3% of the patients after 4 th session, in 91.1% after 5th session and in 91.7% of the patients after 6th session. The progression of alopecia by chemotherapy sessions was similar in both chemotherapy combinations (Table IV) . (4) .
Hematologic toxicity is significant with paclitaxel. Severe neutropenia is seen in 35-75% of the patients (5) . Usually, anemia and thrombocytopenia is mild. Peripheral neuropathy is another toxicity caused by paclitaxel, which is important and impairs life quality of the patient (6) . The development of alopecia is undoubted with the doses over 130 mg/m 2 .
With the use of cisplatin, the most common side effects involve neurotoxicity, nephrotoxicity, moderate-degree bone marrow suppression, allergic reactions and severe nausea and vomiting. Nephrotoxicity is dose-dependent and develops in case the serum level of the drug exceeds 6 µg/ml (5) .
Carboplatin-mediated bone marrow suppression is the main toxicity seen during the use of this drug; this toxicity is dose-dependent and mostly reversible. Anemia develops in 60-70% of the patients and grade 4 neutropenia occurs in 15-20% of the patients (5) .
Many anti-cancer drug classes may cause alopecia, however, alopecia occurs more often with four major drug groups. Alopecia develops in more than 80% of the patients with anti-microtubule agents (paclitaxel, etc.), in more than 60% of the patients using alkylating agents (cyclophosphamide, etc.), in 60-100% of the patients given topoisomerase inhibitors (doxorubicin, etc.) and in 10-50% of the patients administered antimetabolites (5FU, leucovorin, etc.) (1) . It was found that combined treatments were more frequently associated with alopecia in comparison with single agent treatments (1, 7) .
In this study, grade 4 alopecia was not observed, however, similar to the literature data, grade 3 alopecia was found in 91.7% of the patients. As the chemotherapy sessions advanced, alopecia became more prominent.
The agent causing alopecia in the chemotherapy protocols was paclitaxel, so that the severity and incidence of this side effect was similar with both chemotherapy combinations.
The development of alopecia is related to the growth cycle of the hair follicle. The growth cycle has basically three phases called anagen, catagen and telogen. Anagen is the phase in which regeneration of hair root, follicular growth and production of hair body occur most intensively. Catagen is the degenerative phase, in which total regression of follicles and apoptosis in some parts occur. In telogen phase, the follicle is stable (7) .
Chemotherapy-induced alopecia occurs when the hair follicles are in anagen phase. Ninety to ninety-five percent of hairs remain in anagen phase for approximately 2 to 6 years. In contrast, 1% of hairs remains in catagen phase for 2-3 weeks, and less than 10% of hairs remain in telogen phase for 3-4 months (8) .
Alopecia affects patient's physical appearance, selfconfidence, sexuality, and patient's fight against cancer in a negative way. In a study with women, it was found that 47% of them perceived alopecia to be the most traumatic side effect, and 8% of women rejected chemotherapy because of alopecia (9, 10) .
Chemotherapy-induced alopecia is usually reversible and approximately 3 to 6 months after treatment, hairs begin to grow again. The re-growing hairs may have changes in hair pattern, grayish in color, and reduced density (1, 11) .
Many treatment protocols have been attempted to prevent chemotherapy-induced alopecia; these involve drug-specific antibodies, certain agents modifying growth cycle (cyclosporine A, minoxidil, AS101), antioxidants (NAC), cytokine and growth factors (EGF, FGF, interleukin 1), apoptosis inhibitors (M50054) and skull skin cooling method (7, 12) . Although some of these protocols shorten the period of chemotherapyinduced alopecia, they are not able to prevent from alopecia because many different chemotherapeutic agent are used together (7) .
In conclusion, the patients should be informed about alopecia that occurs often due to chemotherapeutic agents used for gynecologic malignancies and they should be assured that this toxicity is most likely transient. So that, patient's compliance to the treatment increases and the chemotherapy can be given throughout the required number of the sessions.
